40627-14-3

Basic information

• Product Name: 2'-Deoxyformycin A
• Synonyms: 2'-Deoxyformycin A
• CAS NO: 40627-14-3
• Molecular Weight: 251.245
• Mol File: 40627-14-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2'-Deoxyformycin A(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-Deoxyformycin A(40627-14-3)
• EPA Substance Registry System: 2'-Deoxyformycin A(40627-14-3)

Safety Data

• Hazardous Substances Data: 40627-14-3(Hazardous Substances Data)

Upstream product

• 40627-37-0 7-amino-3-<5-O-(2-acetoxyisobutyryl)-2-bromo-2-deoxy-β-D-arabinofuranosyl>-1H-pyrazolo<4,3-d>pyrimidine 
• 96807-07-7 3-((2S,3S,3aR,9aR)-5,5,7,7-Tetraisopropyl-3-trimethylsilanyloxy-tetrahydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-ylamine 
• 57101-52-7 formycin 
• 87791-95-5 7-amino-3-<3',5'-O-(1,1,3,3-tetraisopropyl-1,3-disiloxanediyl)-β-D-ribofuranosyl>pyrazolo<4,3-d>pyrimidine 
• 96807-08-8 7-amino-3-<3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2-deoxy-β-D-erythro-pentofuranosyl>pyrazolo<4,3-d>pyrimidine 
• 40635-67-4 acetoxyisobutyryl bromide 
• 96807-06-6 7-amino-3-<3',5'-O-(1,1,3,3-tetraisopropyl-1,3-disiloxanediyl)-2'-(phenoxythiocarbonyl)-β-D-ribofuranosyl>pyrazolo<4,3-d>pyrimidine 

Downstream Products

• 172878-92-1 N'-(3-{(2R,4S,5R)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-hydroxy-tetrahydro-furan-2-yl}-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-N,N-dimethyl-formamidine 

Relevant articles and documents

Improved synthesis of 2'-deoxyformycin A and studies of its in vitro activity against mouse lymphoma of T-cell origin

7-Amino-3-(2'-deoxy-β-D-ribofuranosyl)pyrazolo[4,3-d]pyrimidine (2'-deoxyformycin A) was synthesized from formycin A by a sequence consisting of (i) 3',5'-cyclosilylation with 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane, (ii) 2'-acylation with phenoxyth

-

-

Nucleic Acid Related Compounds. 51. Synthesis and Biological Properties of Sugar-Modified Analogues of the Nucleoside Antibiotics Tubercidin, Toyocamycin, Sangivamycin, and Formycin

Treatment of 7-amino-3-β-D-ribofuranosylpyrazolopyrimidine (formycin) with α-acetoxyisobutyryl bromide followed by deprotection of the resulting trans-vicinal acetoxy bromides and hydrogenolysis of the separated bromohydrins gave 2'-deoxy- (23 percent) and 3'-deoxyformycin (32 percent) after complete deprotection and purification of their hydrochloride salts.An analogous sequence gave 3'-deoxytoyocamycin and/or 3'-deoxysangivamycin in ca. 80 percent yields from toyocamycin.Antiviral, antineoplastic, and antimetabolic effects were evaluated for the formycin compounds and 4-amino-7-β-D-ribofuranosylpyrrolopyrimidine (tubercidin), its 5-cyano- (toyocamycin), and 5-carbamoyl- (sangivamycin) antibiotic congeners in comparison with their 2'-deoxy, 3'-deoxy, and arabino analogues.In all cases, the modified-sugar compounds were less cytotoxic than the parent antibiotics.The majority also exhibited lower antiviral potency.However, the xylo-tubercidin analogue retained potent antiherpes 1 and 2 activity with decreased cytotoxity.Labeled metabolite studies suggested that effects of these compounds on RNA and/or protein synthesis might be more significant than interference with DNA synthesis.